Managers / Q1 2026
Patient Square Capital LP
CIK 0001819257 · 2884 SAND HILL ROAD, SUITE 100, MENLO PARK, CA, 94025 · 212-446-4600
Reported Value
$564M
Q1 2026
Positions
29
Filings on Record
14
2019–present window
Filed
May 15, 2026
original filing
Summary
Patient Square Capital Lp reported $564M in U.S.-listed holdings across 29 positions for Q1 2026.
The portfolio is heavily concentrated: Roivant Sciences alone accounts for 40.1% of reported value.
Compared with Q4 2025, the fund opened 7 new positions and exited 6.
Reported Value by Quarter
13F Reported Value
Portfolio Composition
By security type
- Other · 42.6% · $240M
- Common Stock · 36.9% · $208M
- ADR · 20.4% · $115M
Quarter-over-Quarter Changes full breakdown →
Holdings — Q1 2026
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $564M | 29 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $467M | 28 | Feb 12, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $374M | 24 | Nov 10, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $277M | 19 | Aug 11, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $242M | 19 | May 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $267M | 20 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $269M | 11 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $215M | 2 | Aug 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $235M | 2 | May 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $183M | 2 | Feb 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $182M | 2 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $205M | 2 | Aug 11, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $124M | 2 | May 10, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $236.5B | 2 | Feb 13, 2023 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.